

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number
WO 2005/105732 A1

(51) International Patent Classification⁷: **C07C 235/42**,
C07D 213/89, A61K 31/166, 31/4412, A61P 29/00

(21) International Application Number:
PCT/IB2005/001134

(22) International Filing Date: 22 April 2005 (22.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/568,088 4 May 2004 (04.05.2004) US

(71) Applicant (for JP only): **PFIZER JAPAN INC.** [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOIKE, Hiroki**
[JP/JP]; Pfizer Global Research and Development, Pfizer
Japan Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun,
Aichi-ken 470-2393 (JP). **MATSUMOTO, Yukari**
[JP/JP]; Pfizer Global Research and Development, Pfizer
Japan Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun,
Aichi-ken 470-2393 (JP). **YAMAGISHI, Tatsuya** [JP/JP];
Pfizer Global Research and Development, Pfizer Japan
Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken
470-2393 (JP). **KON-I, Kana** [JP/JP]; Pfizer Global
Research and Development, Pfizer Japan Inc., 2, Aza
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393
(JP). **OKUMURA, Yoshiyuki** [JP/JP]; Pfizer Global
Research and Development, Pfizer Japan Inc., 2, Aza

5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393
(JP). **NAKAO, Kazunari** [JP/JP]; Pfizer Global Research
and Development, Pfizer Japan Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS



(57) Abstract: This invention provides a compound of the
formula (I), wherein X represents a carbon atom or the like:
Y represents imino, or the like: R¹ represents an alkyl group
having from 1 to 6 carbon atoms or the like: R² and R³ in-
dependently represents a hydrogen atom or the like. These
compounds are useful for the treatment of disease condi-
tions mediated by prostaglandin such as pain, or the like in
mammalian. This invention also provides a pharmaceutical
composition comprising the above compound.



WO 2005/105732 A1